
The Journal of Neuromuscular Diseases can now be found on Bluesky. Find us and connect at @journalnd.bsky.social. bsky.app/profile/journalnd.b… #neuromusculardisorders #journal_nd

JND | Dedicated to expediting our understanding & improving treatments of neuromuscular diseases | Editors: Carsten G. Bönnemann & Hanns Lochmüller

The Journal of Neuromuscular Diseases can now be found on Bluesky. Find us and connect at @journalnd.bsky.social. bsky.app/profile/journalnd.b… #neuromusculardisorders #journal_nd

📄 New study in JND: Therapeutic inertia in #MyastheniaGravis is common ~80% of neurologists failed to escalate treatment in ≥2 scenarios. Key drivers: • Resistance to new therapies • Low organisational support Full report here: buff.ly/TuupmaU

📄 New review in JND: Somatic instability in DM1 CTG repeat expansions: • Grow over time • Vary by tissue (muscle > blood) • Are shaped by DNA repair (MMR, FAN1) Read the open access review here: buff.ly/VcelXQu #DM1 #RepeatExpansion #Genetics #RareDisease

📄 New in Journal of Neuromuscular Diseases: Sirolimus may help manage steroid-refractory hepatotoxicity following #AAV gene therapy in #DMD. In 4 cases, liver enzymes improved, allowing steroid tapering. Important insights for safety & monitoring: buff.ly/otZi5hl

📄 New in JND Muscle MRI detects early, subtype-specific patterns in idiopathic inflammatory myopathies: buff.ly/ihGdZJG ✔️ Distinct signatures across IBM, DM, PM, ASYS, IMNM ✔️ Correlates with muscle strength & CK #Myositis #MRI #Neuromuscular

New in JND Expanded characterization of autosomal recessive HMGCR-related limb-girdle muscular dystrophy. 🧬 6 families, 11 patients 🧬 3 novel variants identified 🧬 Broader phenotype incl. congenital onset & liver involvement buff.ly/UhlmShr #LGMD #RareDisease

📄 New study: A novel implantable catheter–port (ThecaFlex DRx) enables repeated intrathecal delivery of nusinersen in SMA. ✔️ 100% implantation success ✔️ 92% received treatment via device ✔️ Promising early safety profile buff.ly/Fwf37nT #SMA #Nusinersen #Neurology

📄 New review in JND How satellite cells are central to muscle regeneration and a growing class of disorders termed satellite cell-opathies, plus their emerging therapies. Read the full review here: buff.ly/n5brzO7 #Neuromuscular

📄 New research in JND: The phase 3 REACH trial evaluated losmapimod in FSHD While the study did not meet its primary endpoint, losmapimod was well tolerated, with insights that may guide future trials. buff.ly/vVwusOF #FSHD #Neuromuscular #RareDisease

📄 From our special issue on RNA therapeutics: A study examining cardiac outcomes in #DMD treated with the exon-skipping therapy eteplirsen. Treated patients showed slower LVEF decline and lower risk of reaching cardiac dysfunction thresholds. buff.ly/ycbsqVl

📄 Next from the JND special issue on RNA therapeutics: A focused review of real-world evidence for nusinersen in #SMA. Data supports sustained motor benefits and a favourable safety profile, Read it here: buff.ly/WISRWey #RNATherapeutics #Neuromuscular

From the JND special issue on RNA therapeutics: Aartsma-Rus & Takeda examine the development of ASO therapies for #Duchenne muscular dystrophy and #SMA. Read the paper here: buff.ly/rJJb5N7 #Neuromuscular #RNAtherapeutics #DMD #SMA

🧬 New Special Issue of JND out today celebrating #RareDiseaseDay: “RNA Therapeutics in Neuromuscular Disorders” RNA-targeted approaches in Duchenne muscular dystrophy, Spinal muscular atrophy, Myotonic dystrophy and more: buff.ly/56IOm0I #Neuromuscular #DMD #SMA #DM1

🎧 New podcast out now! Prof Laurent Servais (joining us from a busy airport) chats with Dr Grace McMacken about the future of newborn screening for neuromuscular disorders. 👉 Listen here: buff.ly/zLMcu3B #SMA #Neuromuscular #NewbornScreening

🫀 Myocarditis is a serious risk after gene therapy for #Duchenne muscular dystrophy (DMD). In this new review paper, Kaufman et al. call for proactive cardiac monitoring & risk stratification to safeguard patients receiving AAV-based therapies. 🔗 buff.ly/mhlJVGK

Knowledge on early motor milestones in #DMD is limited, but this is essential given increasing newborn screening and earlier ages in clinical trials. 📑 This research study by Lowes et al sheds new light on DMD in <5 year age group. ➡️ Full report here buff.ly/x1Y7sCl